Literature DB >> 12475695

Prognostic value of proliferative activity and nuclear morphometry for progression in TaT1 urothelial cell carcinomas of the urinary bladder.

Marco G W Bol1, Jan P A Baak, Simon Rep, Willem L Marx, Arnold Jan Kruse, Siebe D Bos, Otto Kisman, Feja J Voorhorst.   

Abstract

OBJECTIVES: To analyze the predictive power of Ki67 area% (Ki67), mitotic activity index (MAI), p53 area% (p53), and the mean area of the 10 largest nuclei (MNA10) for progression of stage in 195 primary consecutive TaT1 urothelial cell carcinomas of the urinary bladder.
METHODS: Ki67- and p53-positive versus negative nuclei, MAI, and MNA10 using motorized systematic random sampling morphometry were determined. Kaplan-Meier curves and multivariate survival analysis (Cox model) were used to assess the prognostic value of the quantitative and classic clinicopathologic risk factors (age, sex, stage, grade, carcinoma in situ, multicentricity).
RESULTS: Thirteen (6.7%) of the 195 patients had progression (0 [0%] of 36 low-risk, 1 [1.1%] of 85 intermediate-risk, and 12 [16.2%] of 74 high-risk patients). In univariate analysis (all variables), the strongest predictors with the highest hazard ratios were Ki67 (threshold 25.0%), MAI (threshold 30), and MNA10 (threshold 170 microm2). In multivariate analysis, the strongest independent combinations for progression--MNA10 (170 microm2) plus MAI (threshold 30) and MNA10 (threshold 170 microm2) plus Ki67 (threshold 25.0%)--overshadowed all other features. p53 was weaker but, combined with Ki67, still predicted progression fairly well. In the total group, the sensitivity, specificity, and positive and negative predictive values of MNA10-MAI and MNA10-Ki67 at the thresholds mentioned were 100%, 89%, 38%, and 100%, respectively. These feature combinations were also strongest prognostically in the high-risk treatment group.
CONCLUSIONS: The combined biomarkers MNA10-MAI or MNA10-Ki67 are accurate, well reproducible, and easy to assess progression predictors in all patients with TaT1 urothelial cell carcinomas, as well as in high-risk (bacille Calmette-Guérin-treated) patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12475695     DOI: 10.1016/s0090-4295(02)01906-4

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  7 in total

1.  DNA ploidy, nuclear size, proliferation index and DNA-hypomethylation in ovarian cancer.

Authors:  Alain G Zeimet; Heidi Fiegl; Georg Goebel; Francis Kopp; Claude Allasia; Daniel Reimer; Ilona Steppan; Elisabeth Mueller-Holzner; Melanie Ehrlich; Christian Marth
Journal:  Gynecol Oncol       Date:  2011-01-20       Impact factor: 5.482

2.  Large and round tumor nuclei in osteosarcoma: good clinical outcome.

Authors:  Carlos E de Andrea; Antonio Sergio Petrilli; Reynaldo Jesus-Garcia; Luiz F Bleggi-Torres; Maria Teresa S Alves
Journal:  Int J Clin Exp Pathol       Date:  2011-01-30

3.  Clinical prognostic factors for radical cystectomy in bladder cancer.

Authors:  Seung Hyun Jeon; Sung-Hyun Jeon; Sung-Goo Chang
Journal:  Cancer Res Treat       Date:  2005-02-28       Impact factor: 4.679

4.  Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomas: identification of subgroups with low and high stage progression risks.

Authors:  M G W Bol; J P A Baak; B van Diermen; S Buhr-Wildhagen; E A M Janssen; K H Kjellevold; A J Kruse; O Mestad; P Øgreid
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

Review 5.  High Ki-67 Immunohistochemical Reactivity Correlates With Poor Prognosis in Bladder Carcinoma: A Comprehensive Meta-Analysis with 13,053 Patients Involved.

Authors:  Yihuan Luo; Xin Zhang; Meile Mo; Zhong Tan; Lanshan Huang; Hong Zhou; Chunqin Wang; Fanglin Wei; Xiaohui Qiu; Rongquan He; Gang Chen
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

6.  Prognostic value and reproducibility of different microscopic characteristics in the WHO grading systems for pTa and pT1 urinary bladder urothelial carcinomas.

Authors:  Vebjørn Kvikstad; Ok Målfrid Mangrud; Einar Gudlaugsson; Ingvild Dalen; Hans Espeland; Jan P A Baak; Emiel A M Janssen
Journal:  Diagn Pathol       Date:  2019-08-14       Impact factor: 2.644

7.  Influence of pre-operative oral carbohydrate loading vs. standard fasting on tumor proliferation and clinical outcome in breast cancer patients ─ a randomized trial.

Authors:  Tone Hoel Lende; Marie Austdal; Anne Elin Varhaugvik; Ivar Skaland; Einar Gudlaugsson; Jan Terje Kvaløy; Lars A Akslen; Håvard Søiland; Emiel A M Janssen; Jan P A Baak
Journal:  BMC Cancer       Date:  2019-11-08       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.